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Heartfailure(HF)isagrowingepidemic withtheannual numberofhospitalizations constantlyincreasingover thelastdecades for
HF as a primary or secondary diagnosis. Despite the emergence of novel therapeutic approached that can prolong life and shorten
hospital stay, HF patients will be needing rehospitalization and will often have a poor prognosis. Telemonitoring is a novel di-
agnostic modality that has been suggested to be beneﬁcial for HF patients. Telemonitoring is viewed as a means of recording
physiological data, such as body weight, heart rate, arterial blood pressure, and electrocardiogram recordings, by portable devices
and transmitting these data remotely (via a telephone line, a mobile phone or a computer) to a server where they can be stored,
reviewed and analyzed by the research team. In this systematic review of all randomized clinical trials evaluating telemonitoring in
chronic HF, we aim to assess whether telemonitoring provides any substantial beneﬁt in this patient population.
1.Introduction
Heart failure (HF) is a growing epidemic, especially in the
western world. Over the last decade, the annual number of
hospitalizations has increased from 800,000 to over a million
for HF as a primary diagnosis and from 2.4 to 3.6 million for
HF as a primary or secondary diagnosis [1]. Approximately
50% of HF patients are rehospitalized within 6 months of
discharge and with the aging of the population this trend
will continue to rise [2, 3]. Understanding the epidemiology
and pathophysiology of the syndrome [4], identifying the
predictors and their strength of association with outcomes,
and cost-eﬀectively using the available diagnostic modalities
are essential in order to devise eﬀective preventive inter-
ventions and implement novel therapeutic approaches to
curb this epidemic [5–8]. Despite, however, the emergence
of novel therapeutic approached that can prolong life and
shorten hospital stay [9–13], these patients will be needing
rehospitalization and will often have a poor prognosis [2].
In Europe, it is estimated that at least 10 million people
suﬀer from chronic HF [14, 15], and in the United States
another 400.000–700.000 patients are diagnosed annually
[16], while 1 in 9 death certiﬁcates (277,193 death) in 2007
mentioned HF [17]. The healthcare costs are equally high;
in one study, it is reported that $30 billion were spent in the
USA in 2007 [18].
Telemonitoring is a novel diagnostic modality that has
been suggested to be beneﬁcial for HF patients [19, 20]. Tele-
monitoring is viewed as a means of recording physiological
data (such as body weight, heart rate, arterial blood pressure2 Cardiology Research and Practice
Table 1: Inclusion and exclusion criteria.
Inclusion criteria
Randomized controlled trials (RCT)
Trials conducted in the previous ten years
At least one device that measures physiological data provided
by the researchers for home use
Intended (per protocol) follow-up period of at least 6 months
Exclusion criteria
Papers that published protocols
Papers that published feasibility data
Papers that published pilot studies
Review papers
Papers not in English
(BP) electrocardiogram (ECG) recordings, and other data)
byportabledevicesandtransmitting thesedataremotely(via
a telephone line, a mobile phone, or a computer) to a server
where they can be stored, reviewed, and analyzed by the
research team.
In this systematic review of all randomized clinical trials
evaluating telemonitoring in chronic HF, we aim to assess
whether telemonitoring provides any substantial beneﬁt in
this patient population.
2. Methods
We searched in Medline, SpringerLink, Scopus, Cinahl, and
Embase for trials that examined eﬃcacy and eﬃciency of
telemonitoring modalities in chronic HF patients. Keywords
usedinthesearchincluded:homecare,telemedicine,teleme-
try, telemonitoring and telehealth combined with chronic
heart failure. This yielded 3378, 322, 288, 130, and 48 papers
respectively. The search lasted for two months and ended
in November 2011. Two of the researchers read all available
titles and abstracts and eliminated duplicate articles. Only
randomizedcontrolledtrialswereincludedthathadafollow-
up period of at least six months, clearly stated a means
of telemonitoring, and were conducted in the previous ten
years.Weexcludedfeasibilityorpilotstudieswhichprimarily
report preliminary ﬁndings of ongoing trials, usually, in
a small number of patients. Table 1 summarizes inclusion
and exclusion criteria. In Figure 1, the selection process is
depicted.
3. Study Characteristics
We identiﬁed 12 randomized controlled trials that met our
inclusion criteria (Tables 2 and 3). Sample sizes varied from
57 [33] to 710 [32] patients. The age of the participants
coveredawiderangefrom44[29]to86years[21].Inmostof
the studies, the functional status of the participants accord-
ing to New York Heart Association’s (NYHA) classiﬁcation
was reported (I–IV) apart from two studies [22, 30]. Two
studies were multinational [24, 27], four were conducted in
the USA [21, 22, 29–31], and the remaining six in Europe
[21, 23, 25, 28, 32, 33].
In most of the studies, the follow-up period ranged from
6to12months,whileinonestudyparticipantswerefollowed
for 26 months (median value) [32]. Three studies did not
clearly state left ventricular ejection fraction (LVEF) [22, 25,
30] and in all of the remaining studies, LVEF was under 40%
except for one (LVEF: 35 ± 15%) [21].
Domestictelephonelinewasthepreferredmeansfordata
transmission in most of the studies, while, in two studies cell
phones were utilized [23, 32], pointing out that mobile and
portableoptionsoﬀeredbytechnologyarebeingincreasingly
adopted in health care.
Researchers collected several physiological data. In the
study by Wade and colleagues [22], body weight and BP
were measured. In the study by Dendale and colleagues [21],
weight, arterial blood pressure, and heart rate were moni-
tored, while in the studies by Scherr and colleagues [23]a n d
Giordano and colleagues [28], patients also reported the
dosage of drugs taken. Goldberg et al. [29]a n dS o r a ne ta l .
[31] recorded weight along with questions regarding HF
symptoms. Cleland et al. [27] and Koehler et al. [32]
monitored weight, arterial blood pressure, and ECG. In the
s t u d yb yM o r t a r ae ta l .[ 24], collection of data included
blood results, dyspnea score, asthenia score, edema score in
addition to weight, heart rate, and systolic blood pressure.
Pulse oximetry was recorded in two studies along with
weight, BP, heart rate and questions regarding symptoms
[25,30].Finally,Antonicellietal.[33]alsomeasured24-hour
urine output.
With regard to primary endpoints, they were similar
across studies. Researchers were mostly interested in mor-
tality (all-cause and/or cardiovascular mortality), rehospital-
ization, or visits to emergency department, expressed either
as bed-days per year or days alive and out of hospital, and,
thirdly, there were combined endpoints including the above.
4.Findings
In all included studies, baseline characteristics of the partic-
ipants did not diﬀer signiﬁcantly between intervention and
control groups. Three studies reported reduced hospitaliza-
tion rates in telemonitoring groups that reached statistical
signiﬁcance [23, 28, 33], and another four studies also found
reductions in hospitalization rates in favor of telemonitoring
without, however, reaching statistical signiﬁcance [21, 27,
28, 30]. In four studies there were more rehospitalizations
in telemonitoring groups compared to usual care groups,
but statistical signiﬁcance was either not reported [25]o r
was not important [22, 31, 32]. Therefore, it could be
argued that survival rates may occur at the expense of
rehospitalization rates. However, in one study, results were
mixed[24];whilethetelemonitoringgroupinItalyhadfewer
hospital admissions compared to Poland and UK (3% versus
11%, P = 0.002), the Polish telemonitoring group had more
readmissions (9% versus 3%, P = 0.13).
With regard to all-cause mortality, three studies reported
statisticallysigniﬁcantresultsthatfavoredthetelemonitoringCardiology Research and Practice 3
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3378 articles
initially identiﬁed
453 possibly relevant
articles remained and full
text was acquired
465 possibly relevant
articles remained
12 remaining
studies included in
the present review
12 additional
articles identiﬁed
by hand search
from references
453 articles were excluded:
1 3 8r e v i e wp a p e r so r
commentaries or editorials,
12 duplicate articles,
302 shorter follow-up period,
or protocols, or feasibility
studies, or pilot studies, or not
RCTs and 1unable to obtain
2923 articles
excluded based on
title and/or abstract
Figure 1: Flowchart of study search.
group [21, 28, 29]. In two of these studies, mean age was rel-
atively low (Table 2). This might implicate that younger age
could be associated with better survival through improved
adherence to medication plan. In the ﬁrst study by Goldberg
et al. [29], compliance was reported to be as high as 98.5%,
while in the study by Giordano et al. [28], the authors report
only that a nurse oﬀered strategies to enhance compliance,
without stating any rates of compliance. Compliance has
beenmeasuredinthepastandinonestudybyDeLusignanet
et al. [34] 75% of the patients recorded their weight suf-
ﬁciently and blood pressure was measured at 90% of the
time in the study. Medication adherence is another key-
factor in this patient population. Wu et al. [35] examined
World Health Organization’ multidimensional adherence
model (MAM) in 134 patients with a mean age of 61 ±
11 years. This model encompasses ﬁve dimensions: (1)
socioeconomicfactors,(2)healthcaresystem-relatedfactors,
(3) condition-related factors, (4) treatment-related factors,
and (5) patient-related factors. In their multivariate analyses,
worse NYHA functional class, more barriers to medication
adherence (i.e., forgetting to take their medication, cost of
medication), minority ethnicity, lower ﬁnancial status, and
lack of perceived social support, but not age nor gender,
were associated with worse objectively measured medication
adherence.
In other four trials, fewer deaths were reported in the
telemonitoring group in comparison to the usual care, how-
ever, these results were not statistically signiﬁcant [22, 26,
31, 32]. In concordance with these positive ﬁndings, another
study reported that there was no death in the telemonitoring
group compared to one death in the control group [23]. In
three studies all-cause mortality was not reported [24, 25,6 Cardiology Research and Practice
30]. Finally, one study reported a death rate of 29% in the
telemonitoring group, 27% in the telephone support group,
and 45% in the usual care group at the ﬁrst year (P = 0.032)
[27].
Another issue that was investigated in three studies was
the cost of hospitalization calculated per patient. One study
foundstatisticallysigniﬁcantreductioninthetelemonitoring
group compared to the usual care group (C 843 ± 1733
versus C 1298 ± 2322, 35% reduction, P<0.01) [28]. In
Tompkins and Orwat’s study [30], there was also a 12%
reduction in the telemonitoring group (P = 0.14). In
contrast, Dendale et al. [21] reported increased costs asso-
ciated with the telemonitoring group (C 1382 ± 3384 versus
C 747 ±2137, P = 0.16).
5. Discussion
Since an aspect of medicine is the continuing attempt to
provide better care to people and HF patients in particular,
it is worth trying to identify the way and means to improve
their quality of life through the best available evidence-based
knowledge. There are several meta-analyses in the literature
that oﬀer an interpretation of ﬁndings after a statistical
process of diﬀerent trials. These results are based on solid
mathematicalprocedures,oﬀeredbyacomputerprogram.In
our opinion, there will always be a degree of error involved,
inherent in all human processes. That is, despite the eﬀort
of all esteemed researchers, there will still be discrepancies
in study designs which may render them not absolutely
comparable.Thereareinclusionandexclusioncriteriadiﬀer-
ences among studies, functional status diﬀerences, outcome
measure discrepancies, and so on.
Currently available trial results may seem rather ambigu-
ous and confusing. Nevertheless, it appears that the above-
presented randomized controlled trials tend to be in favor of
telemonitoring. It could be argued that in some studies
sample sizes were small and thus underpowered to detect
signiﬁcant associations. Importantly, however, an improved
quality of life—a soft end-point gaining more and more clin-
ical signiﬁcance—has been reported in all studies, whereas
telemonitoringwashighlyacceptablebychronicHFpatients.
Key components that patients with HF encounter
through their contact with healthcare services should be
sample in order to design larger scale studies that could test
their value. Small-sized trials may provide some insight;
however, this should always be veriﬁed by larger trials. In
the ﬁeld of telemonitoring, protocols should be clear before-
hand. It may be of great importance in case participants are
asked to monitor their status daily or every other day. Patient
education is also important and documentation of learning
goals and results should be provided, a task that can be un-
dertaken by experienced nurses.
Another urgent need is the identiﬁcation of patients that
would actually be beneﬁted by such interventions. Since the
resources are getting scarce and in a time when cutbacks
and cost reductions are getting bigger, sustainability of
telemonitoring approaches seems diﬃcult. Consequently, a
key factor that will inﬂuence the future implementation of
telemonitoring strategies is the availability of human and
economic resources.
Disclaimer
This paper has been authored within the context of
the Renewing Heath project http://www.renewinghealth.eu/.
The Renewing Health project is partially funded under
the ICT Policy Support Programme (ICT PSP) as part
of the Competitiveness and Innovation Framework Pro-
gramme by the European Community (link to the ICT PSP
website: http://ec.europa.eu/information society/activities/
ict psp/index en.htm). This paper reﬂects only the author’s
views and the European Community is not liable for any use
that might be made of the information contained therein.
Authors’ Contribution
G.GiamouzisandD.Mastrogiannishavecontributedequally
to this paper.
Conﬂict of Interests
The authors declare that there is no conﬂict of interests.
References
[1] G. Giamouzis, F. Triposkiadis, J. Butler, D. Westermann, and
G. Giannakoulas, “Heart failure,” Cardiology Research and
Practice, vol. 2011, Article ID 159608, 2011.
[2] G. Giamouzis, A. Kalogeropoulos, V. Georgiopoulou et al.,
“Hospitalization epidemic in patients with heart failure: risk
factors, risk prediction, knowledge gaps, and future direc-
tions,” Journal of Cardiac Failure, vol. 17, no. 1, pp. 54–75,
2011.
[3] M. Mujib, G. Giamouzis, S. A. Agha et al., “Epidemiology
of stroke in chronic heart failure patients with normal sinus
rhythm: ﬁndings from the DIG stroke sub-study,” Interna-
tional Journal of Cardiology, vol. 144, no. 3, pp. 389–393, 2010.
[4] F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis,
G. Louridas, and J. Butler, “The sympathetic nervous system
in heart failure. Physiology, pathophysiology, and clinical
implications,” Journal of the American College of Cardiology,
vol. 54, no. 19, pp. 1747–1762, 2009.
[5] G. Gambassi, S. A. Agha, X. Sui et al., “Race and the natural
history of chronic heart failure: a propensity-matched study,”
Journal of Cardiac Failure, vol. 14, no. 5, pp. 373–378, 2008.
[6] G. Giamouzis and J. Butler, “Relationship between heart
failure and lipids: the paradigm continues to evolve,” Journal
of Cardiac Failure, vol. 13, no. 4, pp. 254–258, 2007.
[7] G.Giamouzis,J.Butler,andF.Triposkiadis,“Renalfunctionin
advancedheartfailure,”CongestiveHeartFailure,v ol.17,no .4,
pp. 180–188, 2011.
[8] G. Giamouzis, X. Sui, T. E. Love, J. Butler, J. B. Young, and
A. Ahmed, “A propensity-matched study of the association of
cardiothoracic ratio with morbidity and mortality in chronic
heart failure,” American Journal of Cardiology, vol. 101, no. 3,
pp. 343–347, 2008.
[9] G. Giamouzis, J. Butler, R. C. Starling et al., “Impact of
dopamineinfusiononrenalfunctioninhospitalizedheartfail-
ure patients: results of the dopamine in acute decompensatedCardiology Research and Practice 7
heart failure (DAD-HF) trial,” Journal of Cardiac Failure, vol.
16, no. 12, pp. 922–930, 2010.
[10] G. Giamouzis, G. Giannakoulas, K. Tsarpalis et al., “Natri-
uretic peptide-guided levosimendan therapy for heart failure:
a promising new approach,” International Journal of Cardiol-
ogy, vol. 128, no. 1, pp. 91–96, 2008.
[11] G.Giamouzis,F.Triposkiadis,andJ.Butler,“Metforminusein
patients with diabetes mellitus and heart failure: friend or
foe?” Journal of Cardiac Failure, vol. 16, no. 3, pp. 207–210,
2010.
[12] S. Mavrogeni, G. Giamouzis, E. Papadopoulou et al., “A 6-
month follow-up of intermittent levosimendan administra-
tion eﬀect on systolic function, speciﬁc activity questionnaire,
and arrhythmia in advanced heart failure,” Journal of Cardiac
Failure, vol. 13, no. 7, pp. 556–559, 2007.
[13] G. Giamouzis, S. A. Agha, O. J. Ekundayo et al., “Inci-
dent coronary revascularization and subsequent mortality in
chronic heart failure: a propensity-matched study,” Interna-
tional Journal of Cardiology, vol. 140, no. 1, pp. 55–59, 2010.
[14] M. Tendera, “Epidemiology, treatment, and guidelines for the
treatment of heart failure in Europe,” European Heart Journal,
Supplement, vol. 7, pp. J5–J9, 2005.
[15] K. Swedberg, J. Cleland, H. Dargie et al., “Guidelines for the
diagnosis and treatment of chronic heart failure: executive
summary (update 2005): the Task Force for the Diagnosis and
TreatmentofChronicHeartFailureoftheEuropeanSocietyof
Cardiology,” EuropeanHeart Journal, vol. 26, no. 11, pp. 1115–
1140, 2005.
[ 1 6 ]J .V a c c a r o ,J .C h e r r y ,A .M .H a r p e r ,a n dM .O ’ C o n n e l l ,
“Utilization reduction, cost savings, and return on investment
for the paciﬁCare chronic heart failure program, “Taking
Charge of Your Heart Health”,” Disease Management, vol. 4,
no. 3, pp. 131–142, 2001.
[17] V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Executive
summary: heart disease and stroke statistics-2011 update: a
reportfromtheAmerican Heart Association,” Circulation,vol.
123, pp. 459–463, 2011.
[ 1 8 ]J .X u a n ,P .T .D u o n g ,P .A .R u s s o ,M .J .L a c e y ,a n dB .W o n g ,
“The economic burden of congestive heart failure in a man-
aged care population,” American Journal of Managed Care, vol.
6, no. 6, pp. 693–700, 2000.
[ 1 9 ]R .A .C l a r k ,S .C .I n g l i s ,F .A .M c A l i s t e r ,J .G .F .C l e l a n d ,a n d
S. Stewart, “Telemonitoring or structured telephone support
programmesforpatientswithchronicheartfailure:systematic
review and meta-analysis,” British Medical Journal, vol. 334,
no. 7600, pp. 942–945, 2007.
[20] M. Clarke, A. Shah, and U. Sharma, “Systematic review of
studies on telemonitoring of patients with congestive heart
failure: a meta-analysis,” Journal of Telemedicine and Telecare,
vol. 17, no. 1, pp. 7–14, 2011.
[21] P. Dendale, G. De Keulenaer, P. Troisfontaines et al., “Eﬀect
of a telemonitoring-facilitated collaboration between general
practitioner and heart failure clinic on mortality and rehos-
pitalization rates in severe heart failure: the TEMA-HF 1
(TElemonitoringintheMAnagementofHeartFailure)study,”
European Journal of Heart Failure, vol. 14, no. 3, pp. 333–334,
2012.
[ 2 2 ]M .J .W a d e ,A .S .D e s a i ,C .M .S p e t t e l le ta l . ,“ T e l e m o n i t o r i n g
with case management for seniors with heart failure,” Ameri-
can Journal of Managed Care, vol. 17, no. 3, pp. e71–e79, 2011.
[23] D. Scherr, P. Kastner, A. Kollmann et al., “Eﬀect of home-
based telemonitoring using mobile phone technology on the
outcome of heart failure patients after an episode of acute
decompensation: randomized controlled trial,” Journal of
Medical Internet Research, vol. 11, no. 3, p. e34, 2009.
[24] A. Mortara, G. D. Pinna, P. Johnson et al., “Home telemon-
itoring in heart failure patients: the HHH study (Home or
Hospital in Heart Failure),” European Journal of Heart Failure,
vol. 11, no. 3, pp. 312–318, 2009.
[25] O. Dar, J. Riley, C. Chapman et al., “A randomized trial of
home telemonitoring in a typical elderly heart failure popu-
lation in North West London: results of the Home-HF study,”
European Journal of Heart Failure, vol. 11, no. 3, pp. 319–325,
2009.
[26] R. Antonicelli, I. Mazzanti, A. M. Abbatecola, and G. Parati,
“Impact of home patient telemonitoring on use of β-blockers
in congestive heart failure,” Drugs and Aging, vol. 27, no. 10,
pp. 801–805, 2010.
[27] J. G. F. Cleland, A. A. Louis, A. S. Rigby, U. Janssens, and
A. H. M. M. Balk, “Noninvasive home telemonitoring for
patients with heart failure at high risk of recurrent admission
and death: the Trans-European Network-Home-Care Man-
agement System (TEN-HMS) study,” Journal of the American
College of Cardiology, vol. 45, no. 10, pp. 1654–1664, 2005.
[28] A. Giordano, S. Scalvini, E. Zanelli et al., “Multicenter ran-
domised trial on home-based telemanagement to prevent
hospital readmission of patients with chronic heart failure,”
International Journal of Cardiology, vol. 131, no. 2, pp. 192–
199, 2009.
[29] L. R. Goldberg, J. D. Piette, M. N. Walsh et al., “Randomized
trial of a daily electronic home monitoring system in patients
with advanced heart failure: the Weight Monitoring in Heart
Failure (WHARF) trial,” American Heart Journal, vol. 146, no.
4, pp. 705–712, 2003.
[30] C. Tompkins and J. Orwat, “A randomized trial of tele-
monitoring heart failure patients,” Journal of Healthcare
Management, vol. 55, no. 5, pp. 312–323, 2010.
[31] O. Z. Soran, I. L. Pi˜ na, G. A. Lamas et al., “A randomized
clinical trial of the clinical eﬀects of enhanced heart failure
monitoring using a computer-based telephonic monitoring
system in older minorities and women,” Journal of Cardiac
Failure, vol. 14, no. 9, pp. 711–717, 2008.
[32] F. Koehler, S. Winkler, M. Schieber et al., “Impact of remote
telemedical management on mortality and hospitalizations in
ambulatorypatientswithchronicheartfailure:thetelemedical
interventional monitoring in heart failure study,” Circulation,
vol. 123, no. 17, pp. 1873–1880, 2011.
[33] R. Antonicelli, P. Testarmata, L. Spazzafumo et al., “Impact
of telemonitoring at home on the management of elderly
patients with congestive heart failure,” Journal of Telemedicine
and Telecare, vol. 14, no. 6, pp. 300–305, 2008.
[34] S. De Lusignan, S. Wells, P. Johnson, K. Meredith, and E.
Leatham, “Compliance and eﬀectiveness of 1 year’s home
telemonitoring. The report of a pilot study of patients with
chronic heart failure,” European Journal of Heart Failure, vol.
3, no. 6, pp. 723–730, 2001.
[35] J. R. Wu, D. K. Moser, M. L. Chung, and T. A. Lennie, “Pre-
dictors of medication adherence using a multidimensional
adherence model in patients with heart failure,” Journal of
Cardiac Failure, vol. 14, no. 7, pp. 603–614, 2008.